A drug made by Astra Zeneca has this weekend been approved to treat cancer patients in China, under a new system designed to fast-track Western medicines into the People’s Republic. The China Food and Drug Administration (CFDA) has approved the British developed lung cancer drug Tagrisso for sale in the country. It has already been approved in other parts of the world, including Europe, America and Japan. Tagrisso treats a specific mutation that affects as many as 40% of Asian patients with lung cancer — higher than the proportion of Caucasian sufferers affected. It is one of the first medicines to receive the green light under the CFDA’s priority review pathway. The fast-track system is intended to give Chinese patients greater access to the best Western… Want to read more? Register with a few details to continue reading this article. Already a subscriber? Truell wants to tuck into Wagamama Whatever happened to Roger Jenkins?
Tagrisso, a drug used to treat cancer patients, has been approved to be fast-tracked to patients in China via a new system created to quickly push through western medicines into the people's republic. Made by British-Swedish pharmaceutical company Astra Zeneca, the drug treats a particular mutation of lung cancer that affects as many as 40% of Asian patients, a higher proportion than among Caucasian sufferers.